A022102
|
Alliance
|
Randomized Phase III trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for First-Line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
A022104
|
Alliance
|
The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet versus Doublet Chemotherapy to Achieve Clinical Response in Patients with Locally Advanced Rectal Cancer
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
A022106
|
Alliance
|
Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
A031102
|
Alliance
|
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel; Ifosfamide; and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
A031201
|
Alliance
|
Phase III Trial of Enzalutamide (NSC # 766085) Versus Enzalutamide; Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
A031501
|
Alliance
|
Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (Ambassador) Versus Observation
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
A031701
|
Alliance
|
A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (DDGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
A031702
|
Alliance
|
A Phase II Study of Ipilimumab, Cabozantinib, and NIvolumab in Rare Genitourinary Cancers (ICONIC)
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
A031704
|
Alliance
|
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
A031801
|
Alliance
|
A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (RADICAL)
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|